Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report)'s share price gapped up before the market opened on Wednesday . The stock had previously closed at $83.40, but opened at $90.92. Blueprint Medicines shares last traded at $93.69, with a volume of 407,216 shares trading hands.
Analyst Ratings Changes
A number of equities research analysts recently commented on the stock. UBS Group initiated coverage on shares of Blueprint Medicines in a report on Thursday, October 24th. They issued a "neutral" rating and a $88.00 price target on the stock. Oppenheimer upped their price target on Blueprint Medicines from $114.00 to $125.00 and gave the company an "outperform" rating in a research report on Monday, July 8th. Baird R W raised Blueprint Medicines to a "strong-buy" rating in a report on Friday, August 2nd. Guggenheim boosted their price objective on Blueprint Medicines from $130.00 to $138.00 and gave the company a "buy" rating in a research note on Friday, August 2nd. Finally, Needham & Company LLC reiterated a "buy" rating and set a $133.00 target price on shares of Blueprint Medicines in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, Blueprint Medicines currently has a consensus rating of "Moderate Buy" and a consensus price target of $118.39.
Check Out Our Latest Research Report on Blueprint Medicines
Blueprint Medicines Price Performance
The business has a 50 day simple moving average of $89.10 and a two-hundred day simple moving average of $98.49. The firm has a market capitalization of $5.59 billion, a P/E ratio of -19.48 and a beta of 0.58. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.65 and a current ratio of 3.71.
Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last posted its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($1.29) by $0.49. Blueprint Medicines had a negative net margin of 56.64% and a negative return on equity of 157.30%. The company had revenue of $138.20 million for the quarter, compared to analysts' expectations of $104.02 million. During the same period in the prior year, the business earned ($2.19) earnings per share. Blueprint Medicines's revenue for the quarter was up 139.9% compared to the same quarter last year. On average, sell-side analysts expect that Blueprint Medicines Co. will post -3.99 EPS for the current fiscal year.
Insider Activity
In related news, insider Philina Lee sold 41,913 shares of the company's stock in a transaction on Monday, August 5th. The shares were sold at an average price of $93.19, for a total value of $3,905,872.47. Following the completion of the transaction, the insider now directly owns 34,729 shares in the company, valued at approximately $3,236,395.51. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Blueprint Medicines news, insider Fouad Namouni sold 3,633 shares of the stock in a transaction that occurred on Thursday, October 3rd. The shares were sold at an average price of $89.32, for a total transaction of $324,499.56. Following the transaction, the insider now directly owns 69,070 shares in the company, valued at $6,169,332.40. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Philina Lee sold 41,913 shares of Blueprint Medicines stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $93.19, for a total transaction of $3,905,872.47. Following the transaction, the insider now directly owns 34,729 shares in the company, valued at $3,236,395.51. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 4.21% of the company's stock.
Hedge Funds Weigh In On Blueprint Medicines
Several institutional investors and hedge funds have recently made changes to their positions in the business. Emerald Advisers LLC boosted its position in Blueprint Medicines by 10.2% during the third quarter. Emerald Advisers LLC now owns 375,866 shares of the biotechnology company's stock valued at $34,768,000 after buying an additional 34,666 shares during the period. Emerald Mutual Fund Advisers Trust lifted its stake in shares of Blueprint Medicines by 3.7% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 288,540 shares of the biotechnology company's stock valued at $26,690,000 after acquiring an additional 10,207 shares during the last quarter. US Bancorp DE lifted its stake in shares of Blueprint Medicines by 147.6% in the 3rd quarter. US Bancorp DE now owns 11,971 shares of the biotechnology company's stock valued at $1,107,000 after acquiring an additional 7,137 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Blueprint Medicines by 65.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,183 shares of the biotechnology company's stock valued at $1,127,000 after acquiring an additional 4,828 shares during the period. Finally, Pallas Capital Advisors LLC grew its position in Blueprint Medicines by 3.2% during the 3rd quarter. Pallas Capital Advisors LLC now owns 5,657 shares of the biotechnology company's stock worth $523,000 after acquiring an additional 176 shares during the last quarter.
Blueprint Medicines Company Profile
(
Get Free Report)
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.
Featured Articles
Before you consider Blueprint Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Blueprint Medicines wasn't on the list.
While Blueprint Medicines currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
